However, tumor resistance resulting from clinical used aromatase inhibitors and antiestrogens is unpredictable.

Then a newer class of drugs, the aromatase inhibitors, was developed.

Now, a new class of agents called aromatase inhibitors have emerged as an alternative.

Letrozole is one of aromatase inhibitors frequently used in treatment of men with oligospermia.

These concepts provide a strong rationale for studies of aromatase inhibitors to prevent breast cancer.

Third generation of aromatase inhibitors appear better than tamoxifen in the adjuvant treatment of postmenopausal women.

Approval of LH-RH analogs and aromatase inhibitors has brought a new era in breast cancer treatment.

Most postmenopausal women who are diagnosed with breast cancer are prescribed anticancer drugs called aromatase inhibitors.

Recent clinical studies suggest that greater responses occur when aromatase inhibitors are used as first line treatment.

Different chemoprevention trials are ongoing to compare different selective estrogen receptor modulators and aromatase inhibitors with tamoxifen.

Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk.

The current findings have implications for current trials evaluating aromatase inhibitors and other chemopreventive agents for this disease.

About 10% of postmenopausal women on aromatase inhibitors take bisphosphonates to help keep their bones strong.

Tamoxifen was the first drug to block the effects of estrogen and the aromatase inhibitors are the next generation.

Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromatase inhibitors or anti-estrogens such as tamoxifen.

It looked at aromatase inhibitors, which stop post-menopausal women producing oestrogen, as oestrogen stimulates the growth of certain breast cancer cells.